ABBV Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 20:01):

Stats
Dagens volum	3.07M
Gjennomsnittsvolum	5.73M
Markedsverdi	283.44B
EPS	$2.79 ( 2024-04-26 )
Neste inntjeningsdato	( $2.79 ) 2024-07-25
Last Dividend	$1.550 ( 2024-04-12 )
Next Dividend	$0 ( N/A )
P/E	59.07
ATR14	$0.0790 (0.05%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-31	Quaggin Susan E	Buy	82	Stock Equivalent Units
2024-03-31	Alpern Robert J	Buy	41	Stock Equivalent Units
2024-03-31	Rapp Edward J	Buy	212	Stock Equivalent Units
2024-03-20	Donoghoe Nicholas	Sell	21 082	Common Stock, $0.01 par value
2024-03-18	Stewart Jeffrey Ryan	Buy	26 110	Common Stock, $0.01 par value

INSIDER POWER
2.46
Last 100 transactions
Buy: 975 676 \| Sell: 912 577

Volum Korrelasjon

Lang: -0.01 (neutral)

Kort: -0.51 (weak negative)

Signal:(28.973) Neutral

Abbvie Inc Korrelasjon

10 Mest positive korrelasjoner
YSAC	0.891
MOS	0.887
TDI	0.882
NANR	0.865
BML-PJ	0.864
CHH	0.864
VAL	0.86
TMO	0.858
VLTA	0.853
PACK	0.847

10 Mest negative korrelasjoner
TGH	-0.863
KURE	-0.861
PBC	-0.86
FRGE	-0.859
ALCC	-0.856
SID	-0.854
CE	-0.847
MX	-0.847
FDD	-0.844
WFC-PD	-0.839

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Abbvie Inc Korrelasjon - Valuta/Råvare

0.40
( neutral )

0.37
( neutral )

0.31
( neutral )

0.38
( neutral )

-0.46
( neutral )

-0.38
( neutral )

Abbvie Inc Økonomi

Annual	2023
Omsetning:	$54.32B
Bruttogevinst:	$45.54B (83.84 %)
EPS:	$2.73

FY	2023
Omsetning:	$54.32B
Bruttogevinst:	$45.54B (83.84 %)
EPS:	$2.73

FY	2022
Omsetning:	$58.05B
Bruttogevinst:	$40.64B (70.00 %)
EPS:	$6.65

FY	2021
Omsetning:	$56.20B
Bruttogevinst:	$38.75B (68.96 %)
EPS:	$6.53

Financial Reports:

No articles found.

Abbvie Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$1.410 (N/A)	$1.410 (N/A)	$1.480 (N/A)	$1.480 (N/A)	$2.96 (N/A)	$1.480 (N/A)	$1.550 (N/A)	$1.550 (N/A)	$0 (N/A)	$0 (N/A)

Abbvie Inc Dividend Information - Dividend King

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.62 - Stable (7.53%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.400	2013-01-11
Last Dividend	$1.550	2024-04-12
Next Dividend	$0	N/A
Payout Date	2024-05-15
Next Payout Date	N/A
# dividends	47	--
Total Paid Out	$44.05	--
Avg. Dividend % Per Year	3.70%	--
Score	5.69	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.62
Div. Directional Score	7.47	--

Next Divdend (Est)
(2024-07-01)

$1.580 Estimate 75.00 %

Dividend Stability

1.00 Excellent

Dividend Score

5.69

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2013	$1.600	4.56%
2014	$1.660	3.19%
2015	$2.02	3.07%
2016	$2.28	3.96%
2017	$2.56	4.10%
2018	$3.59	3.65%
2019	$4.28	4.80%
2020	$4.72	5.27%
2021	$5.20	4.93%
2022	$5.64	4.16%
2023	$7.40	4.56%
2024	$3.10	1.94%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50
SRV	Dividend Royal	2023-12-04	Monthly	18	7.53%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0895	1.500	8.21	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0361	1.200	8.80	10.00	[0 - 0.3]
returnOnEquityTTM	0.400	1.500	6.66	10.00	[0.1 - 1]
payoutRatioTTM	2.17	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	0.872	0.800	-0.639	-0.512	[1 - 3]
quickRatioTTM	0.633	0.800	-0.980	-0.784	[0.8 - 2.5]
cashRatioTTM	0.339	1.500	9.23	10.00	[0.2 - 2]
debtRatioTTM	0.441	-1.500	2.65	-3.98	[0 - 0.6]
interestCoverageTTM	7.54	1.000	8.32	8.32	[3 - 30]
operatingCashFlowPerShareTTM	12.93	2.00	5.69	10.00	[0 - 30]
freeCashFlowPerShareTTM	12.49	2.00	3.75	7.51	[0 - 20]
debtEquityRatioTTM	5.73	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.685	1.000	1.913	1.913	[0.2 - 0.8]
operatingProfitMarginTTM	0.259	1.000	6.82	6.82	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.385	1.000	8.97	8.97	[0.2 - 2]
assetTurnoverTTM	0.403	0.800	-0.645	-0.516	[0.5 - 2]
Total Score				10.32

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	57.96	1.000	4.25	0	[1 - 100]
returnOnEquityTTM	0.400	2.50	7.86	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	12.49	2.00	5.84	7.51	[0 - 30]
dividendYielPercentageTTM	4.77	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	12.93	2.00	5.69	10.00	[0 - 30]
payoutRatioTTM	2.17	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	-1.017	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.420	1.000	1.988	0	[0.1 - 0.5]
Total Score				4.62

Abbvie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.